{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T01:46:38Z","timestamp":1776303998863,"version":"3.50.1"},"reference-count":28,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T00:00:00Z","timestamp":1629590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>This systematic review and meta-analysis of randomized controlled trials (RCTs) compared the clinical efficacy and safety of anti-MRSA cephalosporin and vancomycin-based treatment in treating acute bacterial skin and skin structure infections (ABSSSIs). PubMed, Embase, Cochrane Central Register of Controlled Trials, Turning Research into Practice, and ClinicalTrials.gov databases were searched for relevant articles from inception to 15 June 2020. RCTs comparing the clinical efficacy and safety of anti-MRSA cephalosporin with those of vancomycin-based regimens in treating adult patients with ABSSSIs were included. The primary and secondary outcomes were clinical response at the test-of-cure assessments and risk of adverse events (AEs), respectively. Eight RCTs were enrolled. The clinical response rate was not significantly different between anti-MRSA cephalosporin and vancomycin-based treatments (odds ratio [OR], 1.05; 95% CI, 0.90\u20131.23; I2 = 0%). Except for major cutaneous abscesses in which anti-MRSA cephalosporin-based treatment was associated with a lower clinical response rate than vancomycin-based treatment (OR, 0.62; 95% CI, 0.40\u20130.97; I2 = 0%), other subgroup analyses according to the type of cephalosporin (ceftaroline or ceftobiprole), type of infection, and different pathogens did not show significant differences in clinical response. Anti-MRSA cephalosporin-based treatment was only associated with a higher risk of nausea than vancomycin-based treatment (OR, 1.41; 95% CI, 1.07\u20131.85; I2 = 0%). In treating ABSSSIs, the clinical efficacy of anti-MRSA cephalosporin is comparable to that of vancomycin-based treatment, except in major cutaneous abscesses. In addition to nausea, anti-MRSA cephalosporin was as tolerable as vancomycin-based treatment.<\/jats:p>","DOI":"10.3390\/antibiotics10081020","type":"journal-article","created":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T21:42:12Z","timestamp":1629668532000},"page":"1020","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Anti-MRSA Cephalosporin versus Vancomycin-Based Treatment for Acute Bacterial Skin and Skin Structure Infection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.3390","volume":"10","author":[{"given":"Ching-Yi","family":"Chen","sequence":"first","affiliation":[{"name":"Division of Chest Medicine, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung 82445, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang-Chun","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Biotechnology and Chemical Engineering, I-Shou University, Kaohsiung 82445, Taiwan"},{"name":"Department of Pharmacy, E-Da Hospital, Kaohsiung 82445, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan 71051, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Ping","family":"Shih","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan 71051, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Jen","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Chi Mei Medical Center, Tainan 71004, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3201\/eid1509.081228","article-title":"Trends in US hospital admissions for skin and soft tissue infections","volume":"15","author":"Edelsberg","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/cid\/ciz980","article-title":"Skin and soft tsue infections in ambulatory care settings: Setting a new trend","volume":"70","author":"Mistry","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/archinte.168.14.1585","article-title":"National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections","volume":"168","author":"Hersh","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/cid\/ciz977","article-title":"National trends in incidence of purulent skin and soft tissue infections in patients presenting to ambulatory and emergency department settings, 2000\u20132015","volume":"70","author":"Fritz","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.idc.2006.09.006","article-title":"Skin and soft tissue infections","volume":"20","author":"Lopez","year":"2006","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.emc.2018.06.005","article-title":"Skin and soft tissue infections in the emergency department","volume":"36","author":"Breyre","year":"2018","journal-title":"Emerg. Med. Clin. N. Am."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.jpedsurg.2010.05.009","article-title":"Emergence of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections as a common cause of hospitalization in United States children","volume":"45","author":"Frei","year":"2010","journal-title":"J. Pediatr. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.idc.2020.10.003","article-title":"Staphylococcal skin and soft tissue infections","volume":"35","author":"Hatlen","year":"2021","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/MOP.0b013e328339421b","article-title":"Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) skin infections","volume":"22","author":"Odell","year":"2010","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","first-page":"29","article-title":"Possible clinical indications of ceftobiprole","volume":"32","year":"2019","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s40265-016-0654-4","article-title":"Ceftaroline fosamil: A review in complicated skin and soft tissue infections and community-acquired pneumonia","volume":"76","author":"Scott","year":"2016","journal-title":"Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ijantimicag.2016.12.016","article-title":"In vitro activity of ceftaroline and comparator agents against Gram-positive and Gram-negative clinical isolates from cancer patients","volume":"49","author":"Rolston","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/sur.2015.209","article-title":"Antimicrobial activity of ceftaroline tested against Staphylococcus aureus from surgical skin and skin structure infections in US medical centers","volume":"17","author":"Sader","year":"2016","journal-title":"Surg. Infect. (Larchmt)"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2008.12.012","article-title":"Ceftobiprole: A novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA)","volume":"34","author":"Barbour","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e02566-e19","DOI":"10.1128\/AAC.02566-19","article-title":"Ceftobiprole activity against bacteria from skin and skin structure infections in the United States from 2016 through 2018","volume":"64","author":"Flamm","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40121-019-0242-5","article-title":"Open-label randomized trial of early clinical outcomes of ceftaroline fosamil versus vancomycin for the treatment of acute bacterial skin and skin structure infections at risk of methicillin-resistant Staphylococcus aureus","volume":"8","author":"Claeys","year":"2019","journal-title":"Infect. Dis. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/jac\/dkq254","article-title":"CANVAS 1, the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Corey","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11096-016-0417-z","article-title":"Ceftaroline fosamil for community-acquired pneumonia and skin and skin structure infections: A systematic review","volume":"39","author":"Turgeon","year":"2017","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"iv53","DOI":"10.1093\/jac\/dkq255","article-title":"CANVAS 2, the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Wilcox","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1086\/526527","article-title":"A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections","volume":"46","author":"Noel","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/AAC.00551-07","article-title":"Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria","volume":"52","author":"Noel","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Overcash, J.S., Kim, C., Keech, R., Gumenchuk, I., Ninov, B., Gonzalez-Rojas, Y., Waters, M., Simeonov, S., Engelhardt, M., and Saulay, M. (2020). Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: Results of a phase 3, randomized, double-blind Trial (TARGET). Clin. Infect. Dis.","DOI":"10.1093\/cid\/ciaa974"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating guidance for reporting systematic reviews: Development of the PRISMA 2020 statement","volume":"134","author":"Page","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1128\/AAC.00590-07","article-title":"Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections","volume":"51","author":"Talbot","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1093\/jac\/dkw333","article-title":"A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities","volume":"71","author":"Dryden","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lan, S.H., Chang, S.P., Lai, C.C., Lu, L.C., and Chao, C.M. (2019). Ceftaroline efficacy and safety in treatment of complicated skin and soft tissue infection: A systemic review and meta-analysis of randomized controlled trials. J. Clin. Med., 8.","DOI":"10.3390\/jcm8060776"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lan, S.H., Lee, H.Z., Lai, C.C., Chang, S.P., Lu, L.C., Hung, S.H., and Lin, W.T. (2021). Clinical efficacy and safety of ceftobiprole in the treatment of acute bacterial skin and skin structure infection: A systematic review and meta-analysis of randomized controlled trials. Expert Rev. Anti-Infect. Ther., 1\u20138.","DOI":"10.1080\/14787210.2021.1927711"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/8\/1020\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:49:20Z","timestamp":1760165360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/8\/1020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,22]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["antibiotics10081020"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics10081020","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,22]]}}}